Clinical Trial Detail

NCT ID NCT03757689
Title Neoadjuvant PD-1 Blockade in Patients With Stage IIB/C Melanoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Abramson Cancer Center of the University of Pennsylvania
Indications

melanoma

Therapies

Pembrolizumab

Age Groups: adult senior

No variant requirements are available.